Ascendis Pharma Endocrinology Division AS
Targeted drugs(Ascendis Pharma Endocrinology Division A/S)은 Immune-related Adverse Event 표적 ADC로, Immune-related Adverse Event; Malignant Solid Tumors 영역에서 개발·상용화 중입니다. 작용기전: target-mediated or intrinsic, which requires only the intrinsic half-life and the target receptor. 전임상 단계입니다. 대표 임상 효능: ORR 15% (ClinicalTrials.gov NCT02285439). 차별점: novel peptidylarginine deiminase 4 (PAD4) inhibitor, against ischemia/reperfusion brain injury by targeting neutrophil extrac.
Immune-related Adverse Event
Immune-related Adverse Event; Malignant Solid Tumors
Recruiting
gene therapy vector and established continuous expression in mice
linkers
AAV delivered lysosome-targeting chimeras mediate sustained antibody depletion in v
novel peptidylarginine deiminase 4 (PAD4) inhibitor, against ischemia/reperfusion brain injury by targeting neutrophil extrac
target-mediated or intrinsic, which requires only the intrinsic half-life and the target receptor
t cells, with an NC/OLA combination treatment showing additive effects on cytotoxicity
apoptosis, oxidative stress, and barrier permeability were assessed via CCK-8, flow cytometry, and FITC-dextran assays
biomarker-guided precision strategy integrated with modern systemic therapy
bypass the BBB via intracranial implantation, nose-to-brain, trigeminal nerve, and transdermal systemic routes
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Ascendis Pharma Endocrinology Division AS
Targeted drugs(Ascendis Pharma Endocrinology Division A/S)은 Immune-related Adverse Event 표적 ADC로, Immune-related Adverse Event; Malignant Solid Tumors 영역에서 개발·상용화 중입니다. 작용기전: target-mediated or intrinsic, which requires only the intrinsic half-life and the target receptor. 전임상 단계입니다. 대표 임상 효능: ORR 15% (ClinicalTrials.gov NCT02285439). 차별점: novel peptidylarginine deiminase 4 (PAD4) inhibitor, against ischemia/reperfusion brain injury by targeting neutrophil extrac.
Immune-related Adverse Event
Immune-related Adverse Event; Malignant Solid Tumors
Recruiting
gene therapy vector and established continuous expression in mice
linkers
AAV delivered lysosome-targeting chimeras mediate sustained antibody depletion in v
novel peptidylarginine deiminase 4 (PAD4) inhibitor, against ischemia/reperfusion brain injury by targeting neutrophil extrac
target-mediated or intrinsic, which requires only the intrinsic half-life and the target receptor
t cells, with an NC/OLA combination treatment showing additive effects on cytotoxicity
apoptosis, oxidative stress, and barrier permeability were assessed via CCK-8, flow cytometry, and FITC-dextran assays
biomarker-guided precision strategy integrated with modern systemic therapy
bypass the BBB via intracranial implantation, nose-to-brain, trigeminal nerve, and transdermal systemic routes
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.